For example, miR-24 targets MT-ND2 in lung carcinoma cells (Michael et al., 2017), miR-26a targets MT-COX2 in prostate cancer (Zhang et al., 2016), miR-4485 targets MT-RNR2 in breast cancer (Sripada et al., 2017). This evidence concerns the gene MCAT and breast carcinoma.